<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038025</url>
  </required_header>
  <id_info>
    <org_study_id>DM94-026</org_study_id>
    <nct_id>NCT00038025</nct_id>
  </id_info>
  <brief_title>A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies</brief_title>
  <official_title>A Phase II Study of Deoxycoformycin (DCF) in Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the side effects and antitumor response of patients&#xD;
      with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deoxycoformycin(DCF)/Pentostatin is a T-cell cytotoxic drug with previously reported&#xD;
      responses in lymphoid malignancies but larger studies are needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 1994</start_date>
  <completion_date type="Actual">November 29, 2006</completion_date>
  <primary_completion_date type="Actual">November 29, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Overall Response</measure>
    <time_frame>Baseline and approximately every 3 weeks thereafter</time_frame>
    <description>Overall responses (OR) of participants with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin defined as Complete Response (CR) and Partial Response (PR).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peripheral T-cell Lymphoma</condition>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Deoxycoformycin (DCF)/Pentostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycoformycin (DCF)</intervention_name>
    <description>Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.</description>
    <arm_group_label>Deoxycoformycin (DCF)/Pentostatin</arm_group_label>
    <other_name>Nipent</other_name>
    <other_name>Pentostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic proof of lymphoid malignancy with an expected complete response rate of&#xD;
             less than 20 percent OR have failed at least one prior therapy.&#xD;
&#xD;
          -  No chemotherapy within 3 weeks of entry into study and must have recovered from acute&#xD;
             toxic effects of prior therapy.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Performance status equal to or less than Zubrod 2.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Patients with measurable disease.&#xD;
&#xD;
          -  Age at least 16 years.&#xD;
&#xD;
          -  Adequate bone marrow function (unless involvement of bone marrow by lymphoma) defined&#xD;
             as AGC greater than 1500 and platelet count greater than 100,000.&#xD;
&#xD;
          -  Adequate hepatic function with a bilirubin less than or equal to 1.5 mg % and SGPT&#xD;
             less than or equal to 4 times the upper limits of normal.&#xD;
&#xD;
          -  Adequate renal function defined as serum creatine less than or equal to 1.5 mg %.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No serious intercurrent illness.&#xD;
&#xD;
          -  Adequate contraception (if applicable).&#xD;
&#xD;
          -  NO patients with significant cardiac disease, i.e. New York Heart Association (NYHA)&#xD;
             class III or IV.&#xD;
&#xD;
          -  NO experimental clinical trial within 3 weeks of study entry.&#xD;
&#xD;
          -  NO patients with active CNS disease.&#xD;
&#xD;
          -  Full recovery from any prior surgical treatment.&#xD;
&#xD;
          -  NO active active infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Razelle Kurzrock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>Public website for M. D. Anderson Cancer Center</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 24, 2002</study_first_submitted>
  <study_first_submitted_qc>May 24, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2002</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycosis Fungoides</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Deoxycoformycin</keyword>
  <keyword>Pentostatin</keyword>
  <keyword>All other lymphomas</keyword>
  <keyword>Nucleoside analogue</keyword>
  <keyword>Adenosine deaminase inhibitor</keyword>
  <keyword>T-cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

